Abstract
No public abstract is available from the verified source records.
Celestine N. Wanjalla
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The end of AIDS: HIV infection as a chronic disease
10.1016/s0140-6736(13)61809-7 · 2013
HIV and aging
10.1016/j.ijid.2016.10.004 · 2016
Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association
10.1161/cir.0000000000000695 · 2019
Inflammation in HIV and its impact on atherosclerotic cardiovascular disease
10.1161/circresaha.124.323891 · 2024
HIV and cardiovascular disease: we need a mechanism, and we need a plan
10.1161/jaha.116.003411 · 2016
Weight gain and integrase inhibitors
10.1097/qco.0000000000000616 · 2020
Metabolic disease in HIV infection
10.1016/s1473-3099(13)70271-8 · 2013
Weight gain before and after switch from TDF to TAF in a U.S. cohort study
10.1002/jia2.25702 · 2021
Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide
10.1097/qai.0000000000003101 · 2023
Antiretrovirals and weight change: weighing the evidence
10.1093/cid/ciae191 · 2024
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods
10.1136/bmj-2023-078378 · 2024
HIV-Infected women gain more weight than HIV-infected men following the initiation of antiretroviral therapy
10.1089/jwh.2017.6717 · 2018
Switch to integrase strand transfer inhibitors during the menopausal transition is associated with accelerated body composition change in women with HIV
10.1093/cid/ciae540 · 2025
Insulin signaling in skeletal muscle of HIV-infected patients in response to endurance and strength training
10.1002/phy2.60 · 2013
Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy
10.1093/cid/civ101 · 2015
Changes in subcutaneous white adipose tissue cellular composition and molecular programs underlie glucose intolerance in persons with HIV
10.3389/fimmu.2023.1152003 · 2023
People with HIV at the end-of-life and their next-of-kin/loved ones are willing to participate in interventional HIV cure-related research
10.1097/qad.0000000000003754 · 2024
Semaglutide and cardiovascular outcomes in obesity without diabetes
10.1056/nejmoa2307563 · 2023
Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension
10.1111/dom.14725 · 2022
A 48-week, randomized controlled trial of doravirine for individuals with HIV and obesity on integrase inhibitors and tenofovir alafenamide: the Do IT Study (ACTG A5391)
10.1093/cid/ciag196 · 2026
To switch or not to switch: are there any antiretroviral strategies to attenuate weight gain in people with HIV?
10.1007/s11904-026-00782-3 · 2026
No additional external references are available.